Catalent Completes Accucaps Acquisition

CDMO Catalent announced that it has completed the acquisition of Accucaps, the Canada-based developer and manufacturer of over-the-counter (OTC), high-potency and conventional pharmaceutical softgels. No financial details of the transaction were disclosed.

The acquisition complements Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity, adding a portfolio of products supplied to pharmaceutical companies in North America, and two state-of-the-art facilities offering integrated softgel development, manufacturing, and packaging. Accucaps’ facilities house sizeable blistering, bottling, and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s. More than 500 employees at Accucaps at the facilities in Windsor and Strathroy, Ontario, have joined Catalent’s network of 11 softgel technologies facilities.